rivaroxaban
bayer,janssen
['rivaroxaban']
use of rivaroxaban did not significantly reduce the composite endpoint of thrombotic events. there was a post-hoc reduction in symptomatic events, but event rates were quite low. #aha22 
Vascular Cardiologist @umichCVC. #thrombosis, #CVcoag, #ImpSci. Co-director @MAQI_2. Board of Directors @AnticoagForum. Tweets my own. RT?endorsement. ??????